Leukotriene receptor antagonist + inhaled corticosteroid combination

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

15 marketed 12 in Phase 3

This page covers all Leukotriene receptor antagonist + inhaled corticosteroid combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Cysteinyl leukotriene receptor 1 (CysLT1) and glucocorticoid receptor, CysLT1 receptor, CysLT1 (cysteinyl leukotriene receptor 1).

Targets

Cysteinyl leukotriene receptor 1 (CysLT1) and glucocorticoid receptor · CysLT1 receptor · CysLT1 (cysteinyl leukotriene receptor 1) · Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2 · CysLT1 receptor (cysteinyl leukotriene type-1 receptor) · Cysteinyl leukotriene receptor 1 · CysLT1 (cysteinyl leukotriene receptor type 1) · CysLT1 receptor (montelukast); H1 histamine receptor (cetirizine) · Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (salmeterol); cysteinyl leukotriene receptors CysLT1 and CysLT2 (montelukast) · Glucocorticoid receptor, beta-2 adrenergic receptor, cysteinyl leukotriene receptor (CysLT1)

Marketed (15)

Montelukast,mometazon froat · Istanbul Training and Research Hospital · Respiratory / Immunology
This combination blocks leukotriene receptors (montelukast) and reduces airway inflammation via glucocorticoid signaling (mometasone furoate) to treat asthma and allergic rhinitis.
Montelukast (High FeNO group) · Hull University Teaching Hospitals NHS Trust · Respiratory
Montelukast is a selective leukotriene receptor antagonist that blocks the action of cysteinyl leukotrienes on the CysLT1 receptor, reducing inflammation and bronchoconstriction.
Comparator: Montelukast · Organon and Co · Respiratory / Immunology
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction.
Singulair · Merck & Co. · Neuroscience
Leukotriene receptor antagonist (LTRA) that blocks CysLT1 receptors, reducing bronchoconstriction, mucus production, and airway inflammation.
Montelukast (drug) · Firestone Institute for Respiratory Health · Respiratory / Immunology
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction.
Placebo to montelukast chewable tablets · Organon and Co · Respiratory / Immunology
Montelukast is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce airway inflammation and bronchoconstriction.
montelukast (Singulair) · University of Bologna · Respiratory / Immunology
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction.
montelukast (MON) · GlaxoSmithKline · Respiratory / Immunology
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction.
Accolate · Strides Pharma Intl · Cardiovascular
Montelukast (Low FeNO group) · Hull University Teaching Hospitals NHS Trust · Respiratory / Immunology
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) to reduce airway inflammation and bronchoconstriction in asthma.
MK0476; montelukast sodium · Organon and Co · Respiratory / Immunology
Montelukast sodium blocks cysteinyl leukotriene receptors (CysLT1) on airway and inflammatory cells, preventing leukotriene-mediated bronchoconstriction and inflammation.
Montelukast placebo granüle · Kecioren Education and Training Hospital · Respiratory / Immunology
Montelukast is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce airway inflammation and bronchoconstriction.
montelukast and cetirizine · Medical University of Lodz · Immunology / Allergy
This combination blocks leukotriene receptors (montelukast) and histamine H1 receptors (cetirizine) to reduce allergic inflammation and symptoms.
Budesonide + Salmeterol + Montelukast · National Heart, Lung, and Blood Institute (NHLBI) · Respiratory / Pulmonology
This combination reduces airway inflammation via corticosteroid action, dilates airways through beta-2 agonist stimulation, and blocks leukotriene-mediated inflammatory pathways.
ICS/LABA and Montelukast · The First Affiliated Hospital of Guangzhou Medical University · Respiratory/Pulmonology
This combination reduces airway inflammation and bronchoconstriction by suppressing inflammatory mediators and relaxing airway smooth muscle.

Phase 3 pipeline (12)

Pranlukast hydrate · SamA Pharmaceutical Co., Ltd · Respiratory
Pranlukast hydrate is a leukotriene receptor antagonist that inhibits the action of leukotrienes, which are involved in the inflammatory process.
fluticasone propionate + montelukast · Milton S. Hershey Medical Center · Respiratory
Fluticasone propionate is a corticosteroid that reduces inflammation, while montelukast is a leukotriene receptor antagonist that prevents bronchospasm.
Montelukast mixed with Loratadine · Innovacion y Desarrollo de Estrategias en Salud · Immunology / Allergy
This combination blocks cysteinyl leukotriene receptors (montelukast) and histamine H1 receptors (loratadine) to reduce allergic inflammation and symptoms.
Montelukast Oral Granules (OG) · Organon and Co · Respiratory / Immunology
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and inflammatory cells, preventing leukotriene-mediated bronchoconstriction and inflammation.
Loratadine/montelukast combination · Organon and Co · Immunology / Allergy / Respiratory
This combination blocks histamine H1 receptors (loratadine) and cysteinyl leukotriene receptors (montelukast) to reduce allergic and inflammatory responses in the airways.
Montelukast + Levocetirizine · Hanmi Pharmaceutical Company Limited · Immunology / Allergy
This combination blocks cysteinyl leukotriene receptors (montelukast) and histamine H1 receptors (levocetirizine) to reduce allergic inflammation and symptoms.
BRL29060A · GlaxoSmithKline · Respiratory/Immunology
BRL29060A is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce inflammatory responses.
Comparator: montelukast/loratadine · Organon and Co · Immunology / Allergy / Respiratory
This is a fixed-dose combination of montelukast (a cysteinyl leukotriene receptor antagonist) and loratadine (a selective H1-receptor antagonist) that reduces airway inflammation and blocks allergic mediators.
Leukotriene Receptor Antagonist · King Abdullah International Medical Research Center · Respiratory / Immunology
Leukotriene receptor antagonists block cysteinyl leukotriene receptors on airway and immune cells, reducing inflammatory mediator signaling.
Comparator: pranlukast · Organon and Co · Respiratory / Immunology
Pranlukast is a cysteinyl leukotriene receptor antagonist that blocks the inflammatory effects of leukotrienes in the airways.
loratadine; montelukast · Organon and Co · Allergy, Asthma
Loratadine is an antihistamine that blocks the action of histamine, a substance in the body that causes allergy symptoms, while montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, substances in the body that cause inflammation and constriction of airways.
SCH 39641 · ALK-Abelló A/S · Immunology / Respiratory
SCH 39641 is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce inflammatory responses.

Patent intelligence

leukotriene receptor antagonist patent landscape — aggregated cliff calendar, attackable patents, originator estates